Featured Research

from universities, journals, and other organizations

Antibody To A Naturally-occurring Sugar Chain In Colon Inhibits Inflammatory Bowel Disease

Date:
October 7, 2005
Source:
Burnham Institute
Summary:
A collaboration led by the Burnham Institute for Medical Research has found that an antibody which binds to an unusual sugar molecule residing in the gut halts the inflammation seen in Crohn's disease and other intestinal inflammations. The antibody could prove to be a promising drug target for these common chronic intestinal disorders.

(La Jolla, Calif.) -- A collaboration led by the Burnham Institute forMedical Research has found that an antibody which binds to an unusualsugar molecule residing in the gut halts the inflammation seen inCrohn's disease and other intestinal inflammations. The antibody couldprove to be a promising drug target for these common chronic intestinaldisorders.

Professor Hudson Freeze, Ph.D., director of Burnham's glycobiologyand carbohydrate chemistry program, together with staff scientistGeetha Srikrishna, Ph.D., and other colleagues found that a naturally"tweaked" sugar chain normally present on white blood cells andintestinal cells plays a role in inflammation. In addition, the teamfound that an antibody produced in reaction to the sugar's presencecurbed intestinal inflammation induced in mice. These findings will bepublished in the October 15th edition of Journal of Immunology.

"We looked at a number of sugar-binding molecules that mayhave had a role in inflammation," said Freeze. "One of the sugar chainselicited an antibody response, so we wondered whether the antibodywould be able to block inflammation in mice. If so, this could haveimplications for inflammatory bowel disease, Crohn's, and also mighthelp combat other autoimmune inflammatory diseases, like arthritis."

The team identified a modified version of very common sugarsknown as N-linked glycans, which are found on the surface of whiteblood cells, as well as normal colon cells. These sugars are also foundin colon tissue of patients suffering from Crohn's disease.

The antibody was tested in a mouse model for Crohn's diseasecreated by transferring white blood cells with the capacity to inducesevere intestinal inflammation into mice with compromised immunesystems. "When administered 10 days after disease onset, the antibodywas able to reverse early symptoms of inflammation and halt furtherprogress of disease," said Srikrishna. The antibody also reduced theaccumulation of white blood cells armed to fight disease and inhibitedthe expression of cellular messengers (cytokines) typically seen ininflammation.

"There are a large number of signaling molecules that areactivated in inflammation," said Freeze. "Antibodies against thesesugar chain molecules, however, appear to curb inflammation beforecytokines associated with inflammation, like NF-kB and TNF, areactivated. The sugar chain must be used at an earlier stage, but in amore specific manner."

The sugar chain's specificity could be crucial to developingtreatments for Crohn's and other inflammatory disorders. The body'sinflammation response usually is a healthy reaction to harmful foreignagents; inflammation disposes of pathogens before they cause disease.Crohn's disease and other inflammatory bowel diseases, generally knownas auto-immune disorders, are a result of the body's immune systemoverreacting to non-existent pathogens, causing the body to attack itsown tissues. The optimal treatment would inhibit excessive inflammationlinked with disease, leaving normal immune function unaffected.

The antibody, Freeze suggests, could prove to be an effectiveremedy for autoimmune disorders if it can act specifically onhyperactive inflammation, while preserving the immune system. RemicadeTM,an antibody-based drug currently used for Crohn's, works by inhibitingthe cytokines that are summoned into action at a later phase of thesediseases.

"Our next step is to identify the molecular players in thebody's early inflammatory response in the intestine," said Freeze. Theteam is focusing on one particular molecule called RAGE (short forReceptor for Advanced Glycation End Products), which has beenimplicated in the pathology of inflammation, as well as cancer,diabetes and Alzheimer's disease. They are also determining the exactmolecular structure of the tweaked sugar chain, and will determine whatother molecules and receptors may interact with it.

Eventually, the researchers hope that they will have enoughpromising information to merit a clinical trial to test the antibody'seffectiveness. "Our antibody was developed for use in mice. We need to"humanize" it, make the antibody suitable for human consumption. Thiscould take some development, but the results could be very beneficial,"Freeze said.

Freeze's and Srikrishna's colleagues included ProfessorMitchell Kronenberg, Olga Turovskaya and Raziya Shaikh of the La JollaInstitute for Allergy and Immunology, Robbin Newlin of Burnham, DirkFoell of the University of Muenster, Germany, and Simon Murch of theUniversity of Warwick, England. The team's research is supported bygrants from the Broad Medical Research Program of The Eli and Edythe L.Broad Foundation and the National Institutes of Health.

###

The Burnham Institute for Medical Research, founded in 1976, is anindependent not-for-profit biomedical research institution dedicated toadvancing the frontiers of scientific knowledge and providing thefoundation for tomorrow's medical therapies. The Institute is home tothree major centers: the Cancer Center, the Del E. Webb Neuroscienceand Aging, and the Infectious and Inflammatory Disease Center. Since1981, the Institute's Cancer Center has been a member of the NationalCancer Institute's prestigious Cancer Centers program. Discoveries byBurnham scientists have contributed to the development of new drugs forAlzheimer's disease, heart disease and several forms of cancer. Todaythe Burnham Institute employs over 700, including more than 550scientists. The majority of the Institute's funding derives fromfederal sources, but private philanthropic support is essential tocontinuing bold and innovative research. For additional informationabout the Institute and ways to support the research efforts of theInstitute, visit www.burnham.org.


Story Source:

The above story is based on materials provided by Burnham Institute. Note: Materials may be edited for content and length.


Cite This Page:

Burnham Institute. "Antibody To A Naturally-occurring Sugar Chain In Colon Inhibits Inflammatory Bowel Disease." ScienceDaily. ScienceDaily, 7 October 2005. <www.sciencedaily.com/releases/2005/10/051007083346.htm>.
Burnham Institute. (2005, October 7). Antibody To A Naturally-occurring Sugar Chain In Colon Inhibits Inflammatory Bowel Disease. ScienceDaily. Retrieved October 2, 2014 from www.sciencedaily.com/releases/2005/10/051007083346.htm
Burnham Institute. "Antibody To A Naturally-occurring Sugar Chain In Colon Inhibits Inflammatory Bowel Disease." ScienceDaily. www.sciencedaily.com/releases/2005/10/051007083346.htm (accessed October 2, 2014).

Share This



More Health & Medicine News

Thursday, October 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pregnancy Spacing Could Have Big Impact On Autism Risks

Pregnancy Spacing Could Have Big Impact On Autism Risks

Newsy (Oct. 1, 2014) A new study says children born less than one year and more than five years after a sibling can have an increased risk for autism. Video provided by Newsy
Powered by NewsLook.com
Robotic Hair Restoration

Robotic Hair Restoration

Ivanhoe (Oct. 1, 2014) A new robotic procedure is changing the way we transplant hair. The ARTAS robot leaves no linear scarring and provides more natural results. Video provided by Ivanhoe
Powered by NewsLook.com
Insertable Cardiac Monitor

Insertable Cardiac Monitor

Ivanhoe (Oct. 1, 2014) A heart monitor the size of a paperclip that can save your life. The “Reveal Linq” allows a doctor to monitor patients with A-Fib on a continuous basis for up to 3 years! Video provided by Ivanhoe
Powered by NewsLook.com
Attacking Superbugs

Attacking Superbugs

Ivanhoe (Oct. 1, 2014) Two weapons hospitals can use to attack superbugs. Scientists in Ireland created a new gel resistant to superbugs, and a robot that can disinfect a room in minutes. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins